ADPT (Adaptive Biotechnologies Corporation) — Stock Analysis, Catalysts & AI Research

Adaptive Biotechnologies Corporation

$17.50

The Read: Adaptive Biotechnologies' stock fell sharply after a Q4 2025 revenue miss overshadowed an EPS beat and then dropped again post-Q1 2026 despite earnings and revenue beats, likely due to insider selling and cautious outlook.

Price

Overlays

Panel

ADPT

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Adaptive Biotechnologies Corporation

$17.50

Health CareBiotechnology

Price

Overlays

Panel

ADPT

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for ADPT

Expected Moves

Adaptive Biotechnologies Corporation

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for ADPT

Expected Moves

Adaptive Biotechnologies Corporation

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow